Amylyx Pharmaceuticals, Inc. (AMLX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-30. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 27/100 (MEDIUM), 41.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 16.18% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Amylyx Pharmaceuticals And 2 More Quality Growth Stocks
- Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
- Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
- Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
- Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
- Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
- Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
- Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Amylyx Pharmaceuticals, Inc..
Full AMLX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.